|
1
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ,
Dobelbower M, et al: Non-small cell lung cancer, version 5.2017,
NCCN clinical practice guidelines in oncology. J Natl Compr Canc
Netw. 15:504–535. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Novello S, Barlesi F, Califano R, Cufer T,
Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, et al:
Metastatic non-small-cell lung cancer: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27
(Suppl 5):v1–v27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morgillo F, Della Corte CM, Fasano M and
Ciardiello F: Mechanisms of resistance to EGFR-targeted drugs: Lung
cancer. ESMO Open. 1:e0000602016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thomas C and Gustafsson JA: The different
roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer.
11:597–608. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Siegfried JM and Stabile LP: Estrongenic
steroid hormones in lung cancer. Semin Oncol. 41:5–16. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marquez-Garban DC, Chen HW, Fishbein MC,
Goodglick L and Pietras RJ: Estrogen receptor signaling pathways in
human non-small cell lung cancer. Steroids. 72:135–143. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Siegfried JM: Smoking out reproductive
hormone actions in lung cancer. Mol Cancer Res. 12:24–31. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stabile LP and Siegfried JM: Estrogen
receptor pathways in lung cancer. Curr Oncol Rep. 6:259–267. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He Q, Zhang M, Zhang J, Chen Y, He J, Shen
J, Liu Y, Zhong S, Jiang L, Yang C, et al: Correlation between
epidermal growth factor receptor mutations and nuclear expression
of female hormone receptors in non-small cell lung cancer: A
meta-analysis. J Thorac Dis. 7:1588–1594. 2015.PubMed/NCBI
|
|
14
|
Nose N, Sugio K, Oyama T, Nozoe T, Uramoto
H, Iwata T, Onitsuka T and Yasumoto K: Association between estrogen
receptor-beta expression and epidermal growth factor receptor
mutation in the postoperative prognosis of adenocarcinoma of the
lung. J Clin Oncol. 27:411–417. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nose N, Uramoto H, Iwata T, Hanagiri T and
Yasumoto K: Expression of estrogen receptor beta predicts a
clinical response and longer progression-free survival after
treatment with EGFR-TKI for adenocarcinoma of the lung. Lung
Cancer. 71:350–355. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Z, Li Z, Ding X, Shen Z, Liu Z, An T,
Duan J, Zhong J, Wu M, Zhao J, et al: ERβ localization influenced
outcomes of EGFR-TKI treatment in NSCLC patients with EGFR
mutations. Sci Rep. 5:113922015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lim VW, Lim WY, Zhang Z, Li J, Gong Y,
Seow A and Yong EL: Serum estrogen receptor beta mediated
bioactivity correlates with poor outcome in lung cancer patients.
Lung Cancer. 85:293–298. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Leung YK, Mak P, Hassan S and Ho SM:
Estrogen receptor (ER)-beta isoforms: A key to understanding
ER-beta signaling. Proc Natl Acad Sci USA. 103:13162–13167. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH,
Zheng MY, Bai XY, Wang Z, Su J, Chen ZH, et al: A comprehensive
review of uncommon EGFR mutations in patients with non-small cell
lung cancer. Lung Cancer. 114:96–102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dahabreh IJ, Linardou H, Siannis F,
Kosmidis P, Bafaloukos D and Murray S: Somatic EGFR mutation and
gene copy gain as predictive biomarkers for response to tyrosine
kinase inhibitors in non-small cell lung cancer. Clin Cancer Res.
16:291–303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Castellanos E, Feld E and Horn L: Driven
by mutations: The predictive value of mutation subtype in
EGFR-mutated non-small cell lung cancer. J Thorac Oncol.
12:612–623. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu HA, Arcila ME, Hellmann MD, Kris MG,
Ladanyi M and Riely GJ: Poor response to erlotinib in patients with
tumors containing baseline EGFR T790M mutations found by routine
clinical molecular testing. Ann Oncol. 25:423–428. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Choi YW, Jeon SY, Jeong GS, Lee HW, Jeong
SH, Kang SY, Park JS, Choi JH, Koh YW, Han JH and Sheen SS: EGFR
Exon 19 deletion is associated with favorable overall survival
after first-line gefitinib therapy in advanced non-small cell lung
cancer patients. Am J Clin Oncol. 41:385–390. 2018.PubMed/NCBI
|
|
24
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mirsadraee S, Oswal D, Alizadeh Y, Caulo A
and van Beek E Jr: The 7th lung cancer TNM classification and
staging system: Review of the changes and implications. World J
Radiol. 4:128–134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Malalasekera A, Tan CSY, Phan V, Yip PY,
Vardy J, Clarke SJ and Kao S: Eastern cooperative oncology group
score: Agreement between non-small-cell lung cancer patients and
their oncologists and clinical implications. Cancer Treat Commun.
5:17–21. 2016. View Article : Google Scholar
|
|
27
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lopez-Rios F, Angulo B, Gomez B, Mair D,
Martinez R, Conde E, Shieh F, Tsai J, Vaks J, Current R, et al:
Comparison of molecular testing methods for the detection of EGFR
mutations in formalin-fixed paraffin-embedded tissue specimens of
non-small cell lung cancer. J Clin Pathol. 66:381–385. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Abe K, Miki Y, Ono K, Mori M, Kakinuma H,
Kou Y, Kudo N, Koguchi M, Niikawa H, Suzuki S, et al: Highly
concordant coexpression of aromatase and estrogen receptor beta in
non-small cell lung cancer. Hum Pathol. 41:190–198. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen W, Zheng R, Zhang S, Zeng H, Fan Y,
Qiao Y and Zhou Q: Esophageal cancer incidence and mortality in
China, 2010. Thorac Cancer. 5:343–348. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Burns TF and Stabile LP: Targeting the
estrogen pathway for the treatment and prevention of lung cancer.
Lung Cancer Manag. 3:43–52. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hsu LH, Liu KJ, Tsai MF, Wu CR, Feng AC,
Chu NM and Kao SH: Estrogen adversely affects the prognosis of
patients with lung adenocarcinoma. Cancer Sci. 106:51–59. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma L, Zhan P, Liu Y, Zhou Z, Zhu Q, Miu Y,
Wang X, Jin J, Li Q, Lv T and Song Y: Prognostic value of the
expression of estrogen receptor β in patients with non-small cell
lung cancer: A meta-analysis. Transl Lung Cancer Res. 5:202–207.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schwartz AG, Prysak GM, Murphy V, Lonardo
F, Pass H, Schwartz J and Brooks S: Nuclear estrogen receptor beta
in lung cancer: Expression and survival differences by sex. Clin
Cancer Res. 11:7280–7287. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Skov BG, Fischer BM and Pappot H:
Oestrogen receptor beta over expression in males with non-small
cell lung cancer is associated with better survival. Lung Cancer.
59:88–94. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Skjefstad K, Grindstad T, Khanehkenari MR,
Richardsen E, Donnem T, Kilvaer T, Andersen S, Bremnes RM, Busund
LT and Al-Saad S: Prognostic relevance of estrogen receptor α, β
and aromatase expression in non-small cell lung cancer. Steroids.
113:5–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sutiman N, Tan SW, Tan EH, Lim WT,
Kanesvaran R, Ng QS, Jain A, Ang MK, Tan WL, Toh CK and Chowbay B:
EGFR mutation subtypes influence survival outcomes following
first-line gefitinib therapy in advanced asian NSCLC patients. J
Thorac Oncol. 12:529–538. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shi Y, Au JS, Thongprasert S, Srinivasan
S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A
prospective, molecular epidemiology study of EGFR mutations in
asian patients with advanced non-small-cell lung cancer of
adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Stewart BW and Wild CP: World Cancer
Report 2014. World Health Organization, IARC Publications. (Lyon,
France). 489–508. 2014.
|
|
40
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Greulich H: The genomics of lung
adenocarcinoma: Opportunities for targeted therapies. Genes Cancer.
1:1200–1210. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: Mutations in lung cancer: Correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Greulich H, Chen TH, Feng W, Jänne PA,
Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR
and Meyerson M: Oncogenic transformation by inhibitor-sensitive and
-resistant EGFR mutants. PLoS Med. 2:e3132005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hsu LH, Chu NM and Kao SH: Estrogen,
estrogen receptor and lung cancer. Int J Mol Sci. 18:E17132017.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Stabile LP, Lyker JS, Gubish CT, Zhang W,
Grandis JR and Siegfried JM: Combined targeting of the estrogen
receptor and the epidermal growth factor receptor in non-small cell
lung cancer shows enhanced antiproliferative effects. Cancer Res.
65:1459–1470. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shen H, Yuan Y, Sun J, Gao W and Shu YQ:
Combined tamoxifen and gefitinib in non-small cell lung cancer
shows antiproliferative effects. Biomed Pharmacother. 64:88–92.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhao XZ, Liu Y, Zhou LJ, Wang ZQ, Wu ZH
and Yang XY: Role of estrogen in lung cancer based on the estrogen
receptor-epithelial mesenchymal transduction signaling pathways.
OncoTargets Ther. 8:2849–2863. 2015. View Article : Google Scholar
|
|
49
|
Fu S, Liu C, Huang Q, Fan S, Tang H, Fu X,
Ai B, Liao Y and Chu Q: Estrogen receptor β1 activation accelerates
resistance to epidermal growth factor receptor-tyrosine kinase
inhibitors in non-small cell lung cancer. Oncol Rep. 39:1313–1321.
2018.PubMed/NCBI
|
|
50
|
Ma S, Yin N, Qi X, Pfister SL, Zhang MJ,
Ma R and Chen G: Tyrosine dephosphorylation enhances the
therapeutic target activity of epidermal growth factor receptor
(EGFR) by disrupting its interaction with estrogen receptor (ER).
Oncotarget. 6:13320–13333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Rosell R, Taron M, Reguart N, Isla D and
Moran T: Epidermal growth factor receptor activation: How exon 19
and 21 mutations changed our understanding of the pathway. Clin
Cancer Res. 12:7222–7231. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yun CH, Boggon TJ, Li Y, Woo MS, Greulich
H, Meyerson M and Eck MJ: Structures of lung cancer-derived EGFR
mutants and inhibitor complexes: Mechanism of activation and
insights into differential inhibitor sensitivity. Cancer Cell.
11:217–227. 2007. View Article : Google Scholar : PubMed/NCBI
|
